- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Medicare Ruling Would Hurt Alzheimer's Patients
The U.S. health care bureaucracy is expanding; both dramatically (e.g. the implementation of the Affordable Care Act) and gradually. A recent decision proposed by the Centers for Medicare & Medicaid Services (CMS) exemplifies the dangers to medical innovation and patients represented by the gradual expansion of the health care bureaucracy.
Large, and expanding, bureaucracies thwart innovation. And, health care bureaucracies are no different. The U.S. health care bureaucracy is expanding; both dramatically (e.g. the implementation of the Affordable Care Act) and gradually. A recent decision proposed by the Centers for Medicare & Medicaid Services (CMS) exemplifies the dangers to medical innovation and patients represented by the gradual expansion of the health care bureaucracy.
CMS has issued a draft decision that, if it were to become effective, would deny payment for a new FDA-approved PET scan technology. This technology can provide certain patients with earlier more accurate diagnosis for Alzheimer’s versus other forms of dementia.
The FDA is the federal agency officially tasked with protecting public health when it comes to ensuring the safety and efficacy of new drugs and medical devices. To fulfill this mission the FDA imposes a long and arduous process on prospective new medical technologies.
Read the full story here: http://onforb.es/14ba6y0
Source: Forbes
Trump Administration’s Message to Supreme Court Puts New Wrinkle in Braidwood Case
February 21st 2025The Trump administration argues that HHS Secretary Robert F. Kennedy Jr can overrule the US Preventive Services Task Force to determine the preventive services covered under the Affordable Care Act.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
5 Key Health Care Moments During President Trump's First Month Back in Office
February 21st 2025President Donald J. Trump pushed for significant health care changes during his first month back in office, through executive orders affecting managed care, drug pricing, and clinical trial diversity guidance.
Read More
NSCLC Advancements Offer Hope, but Disparities Persist
February 20th 2025Ioana Bonta, MD, Georgia Cancer Specialists, discusses the evolving state of non-small cell lung cancer (NSCLC) treatments, their impact on patient outcomes, and the need to address ongoing disparities in these populations.
Read More
